Cellectar Biosciences, Inc. CLRB
1.80
(0.28)
(13.46%)
as of 25 Sep
- Market cap
- $19.6M
- P/E
- 0.0×
Follow CLRB
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
6.66 | 1.90 | 2.96 | 2.77 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.75 | 1.41 | 2.34 | 2.55 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 2.30% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.04 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.87 | 0.86 | 0.82 | 0.96 | |
Capex/Depreciation |
0.00 | 0.03 | (0.12) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.49) | (1.14) | (1.67) | (1.35) | |
Cash per Share |
2.78 | 1.97 | 5.06 | 3.97 | |
Shareholders Equity per Share |
2.44 | 0.79 | 3.27 | 2.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.44 | 0.79 | 3.27 | 2.53 | |
Free Cash Flow |
(6.01) | (4.85) | (4.35) | (4.28) | |
Working Capital |
29.64 | 4.39 | 9.29 | 8.71 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | — | |
Net Current Asset Value |
28.11 | 1.48 | 7.60 | 6.99 | |
| Other line items | |||||
Quick Ratio |
6.49 | 1.71 | 2.78 | 2.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.49) | (1.14) | (1.67) | (1.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
4.95 | 4.30 | 6.00 | 6.16 | |
Average Assets |
25.17 | 13.58 | 20.23 | 25.96 | |
Average Common Equity |
17.72 | 5.27 | 10.90 | 4.51 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates